Drug profile · INN
palopegteriparatide
YORVIPATH
palopegteriparatide (YORVIPATH) is a parathyroid hormone receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — palopegteriparatide
- US status
- approved
- Class
- Systemic hormonal preparations (H05)
- Route
- SUBCUTANEOUS
- Patents
- 8
- Programs
- 1
- Data quality
- 0.84
Quick answer
palopegteriparatide (YORVIPATH) is a parathyroid hormone receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Parathyroid hormone receptor agonist
Primary target: Parathyroid hormone/parathyroid hormone-related peptide receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025051711
TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE
granted -
WO 2024094673
RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH
granted -
CA 3230895
TRAITEMENTS AVEC DES COMPOSES PTH A ACTION PROLONGEE
granted -
CA 3192772
AMELIORATION DU BIEN-ETRE PHYSIQUE ET MENTAL DE PATIENTS ATTEINTS D'HYPOPARATHYROIDISME
granted -
CA 3161101
TRAITEMENT DE L'HYPOPARATHYROIDISME
granted -
US 2020276276
PTH Prodrugs
granted -
US 2019282668
PTH Compounds with Low Peak-To-Trough Ratios
granted -
MA 46343
SCHÉMA POSOLOGIQUE POUR UN COMPOSÉ DE PTH À LIBÉRATION CONTRÔLÉE
granted
Frequently asked questions
What is palopegteriparatide?
palopegteriparatide (YORVIPATH) is a parathyroid hormone receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for palopegteriparatide?
YORVIPATH is a marketed brand name for palopegteriparatide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of palopegteriparatide?
palopegteriparatide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.